CBIO insider trading — Crescent Biopharma, Inc.
Over the last 90 days, insiders at Crescent Biopharma, Inc. (CBIO) made 1 open-market purchase worth $12.38M and 0 open-market sales worth $0, making them net buyers by $12.38M. The largest purchase was by Fairmount Funds Management Llc, Fairmount Healthcare Fund Ii L.P., Kiselak Tomas, Harwin Peter Evan (Director), who bought 853,450 shares for $12.38M on Jul 16, 2026.
Updated Oct 16, 2026.
Recent CBIO insider transactions
Every Form 4 filed by Crescent Biopharma, Inc. officers, directors and 10% owners in the last 90 days, newest first. P = open-market purchase, S = open-market sale; other codes are awards, option exercises, tax withholding or gifts.
| Trade date | Insider | Role | Type | Ownership | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| Sep 16, 2026 | Pinkas Jan | Chief Scientific Officer | S · Sale · 10b5-1 | Direct | 658 | $17.90 | $12K | Form 4 |
| Sep 16, 2026 | Lynch Ryan | See Remarks | S · Sale · 10b5-1 | Direct | 240 | $17.90 | $4K | Form 4 |
| Sep 18, 2026 | Brumm Joshua T | Chief Executive Officer | S · Sale · 10b5-1 | Direct | 7,837 | $16.71 | $131K | Form 4 |
| Sep 16, 2026 | Brumm Joshua T | Chief Executive Officer | S · Sale · 10b5-1 | Direct | 1,610 | $17.90 | $29K | Form 4 |
| Sep 16, 2026 | Bispham Barbara Harlin | See Remarks | S · Sale · 10b5-1 | Direct | 620 | $17.90 | $11K | Form 4 |
| Sep 16, 2026 | Im Ellie Eunkyung | Chief Medical Officer | S · Sale · 10b5-1 | Direct | 623 | $17.90 | $11K | Form 4 |
| Sep 16, 2026 | Scalzo Richard William | Chief Financial Officer | S · Sale · 10b5-1 | Direct | 568 | $17.90 | $10K | Form 4 |
| Sep 18, 2026 | Mcneill Jonathan | President and COO | S · Sale · 10b5-1 | Direct | 3,839 | $16.71 | $64K | Form 4 |
| Sep 16, 2026 | Mcneill Jonathan | President and COO | S · Sale · 10b5-1 | Direct | 731 | $17.90 | $13K | Form 4 |
| Jul 16, 2026 | Fairmount Funds Management Llc, Fairmount Healthcare Fund Ii L.P., Kiselak Tomas, Harwin Peter Evan | Director | P · Purchase | Indirect | 853,450 | $14.50 | $12.38M | Form 4 |
CBIO insider trading FAQ
Are insiders buying CBIO stock?
Yes. In the last 90 days, Crescent Biopharma, Inc. insiders made 1 open-market purchase totaling $12.38M, and no open-market sales. Purchases with the insider's own money are generally seen as a stronger signal than sales, which happen for many reasons (taxes, diversification, planned 10b5-1 sales).
Who are the insiders trading CBIO?
Recent buyers: Fairmount Funds Management Llc, Fairmount Healthcare Fund Ii L.P., Kiselak Tomas, Harwin Peter Evan.
Where does CBIO insider trading data come from?
Every transaction comes from SEC Form 4 filings on EDGAR. Company officers, directors and 10% owners must file a Form 4 within two business days of buying or selling. InsiderBolt reads these filings directly from the SEC.
More stocks with insider activity
Insider trading data is for informational purposes only and is not investment advice. Filings can be amended; always confirm details on SEC EDGAR.